Please login to the form below

Immuno-oncology: The market opportunity for PD-1/PD-L1s


Immuno-oncology is the new frontier in cancer treatment. Using the body’s own immune system to treat cancer, new therapies are producing impressive survival benefits, with reduced side effects. Of these therapies, immune checkpoint inhibitors are showing particular promise.Our latest infographic is a snapshot of the PD-1/PD-L1 market at this time.

http://www.researchpartnership.com/news/2016/08/infographic-immunno-oncology/

23rd November 2016

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Cool heads in a crisis?
Understanding the role pharmaceutical companies can play in fighting today’s global health pandemics
Research Partnership
Biosimilars: Bringing patients into the conversation
Published in eyeforpharma January 2017 by Mariel Metcalfe
Research Partnership
Access and elimination: the future of DAAs in hepatitis C
Published in Pharmaphorum January 2017
Research Partnership
EphMRA One Day Meeting
We are delighted to be attending and presenting a paper at the EphMRA one day meeting on Tuesday 21st February, in London
Research Partnership
Video: Segmentation research

Research Partnership
Pharmaceutical Market Research Conference 2017
We are delighted to be exhibiting and presenting a paper at the Pharmaceutical Market Research Conference 1-2 February in Parsippany, NJ.
Research Partnership